Key facts
- This page summarizes Jonathan P. DiVincenzo's Form 4 filing for LABORATORY CORP OF AMERICA HOLDINGS (LH).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Mar 2024, 17:15.
Jonathan P. DiVincenzo - 27 Mar 2024 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)
- Reporting relationship
- EVP, Pres, Central Labs & Intl
- Issuer ticker
- LH
- Reported as of
- 27 Mar 2024
- Net transaction value
- -$206,175
- SEC form
- 4
- Accepted by SEC
- 29 Mar 2024, 17:15:41 UTC
- Prior SEC filing
- 22 Feb 2024
- Next SEC filing
- 17 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra D. van der Vaart, Attorney-in-Fact for Jonathan P. DiVincenzo
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Jonathan P. DiVincenzo filed Form 4 for LABORATORY CORP OF AMERICA HOLDINGS (LH) on 29 Mar 2024.
Change
- Previous filing in this sequence was filed on 22 Feb 2024.
- Current net transaction value: -$206,175.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LH
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,012
- Change %
- +89%
- Price
- Shares after
- 6,413
- Date
- 27 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
LH
transaction
Common Stock
Tax liability
- Transaction value
- -$206,175
- Shares
- -952
- Change %
- -15%
- Price
- $216.57
- Shares after
- 5,461
- Date
- 27 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LH
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -3,012
- Change %
- -61%
- Price
- Shares after
- 1,965
- Date
- 27 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,012
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.
Footnote F2
Stock withholding to satisfy tax withholding obligations.
Footnote F3
As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.
Footnote F4
This number reflects the aggregate number of RSUs held by the reporting person.